Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anaplastic Lymphoma Kinase (ALK)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT05534854
What this trial is testing

Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes

Who this might be right for
Renal Tumor HistologyKidney CancerRenal Cell Carcinoma+11 more
RenJi Hospital 500
Early research (Phase 1)Looking for participantsNCT07140016
What this trial is testing

Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive
Astellas Pharma Global Development, Inc. 40
Not applicableNot Yet RecruitingNCT07045610
What this trial is testing

Primary Resistance Mechanisms of ALK TKIs

Who this might be right for
ALK-positive Advanced NSCLC PatientsPrimary ResistanceNGS
National Taiwan University Hospital 20
Large-scale testing (Phase 3)Active Not RecruitingNCT03052608
What this trial is testing

Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 296
Not applicableActive Not RecruitingNCT05721950
What this trial is testing

Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Takeda 154
Not applicableStudy completedNCT03718117
What this trial is testing

Descriptive Observational Study ALK-2016-CPHG

Who this might be right for
NSCLCCrizotinibALK Gene Rearrangement or ROS1 Gene Rearrangement
Pfizer 73
Early research (Phase 1)Study completedNCT01742286
What this trial is testing

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Who this might be right for
ALK-activated Tumors
Novartis Pharmaceuticals 83
Testing effectiveness (Phase 2)Study completedNCT02094573
What this trial is testing

Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Ariad Pharmaceuticals 222
Not applicableUnknownNCT06410040
What this trial is testing

A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis

Who this might be right for
ALK-positive Non-small Cell Lung CancerBrain MetastasesMeningeal Metastasis
Sichuan Cancer Hospital and Research Institute 28
Post-approval studies (Phase 4)Ended earlyNCT03672643
What this trial is testing

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Who this might be right for
ALK or ROS1-positive NSCLC
Pfizer 41
Testing effectiveness (Phase 2)Study completedNCT03049618
What this trial is testing

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Who this might be right for
ALK Gene MutationBRAF Gene MutationEGFR Gene Mutation+9 more
University of Southern California 42
Testing effectiveness (Phase 2)WithdrawnNCT05948462
What this trial is testing

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

Who this might be right for
Lung CancerNon-small Cell Lung Cancer
SCRI Development Innovations, LLC
Early research (Phase 1)Study completedNCT01634763
What this trial is testing

Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Who this might be right for
Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
Novartis Pharmaceuticals 22
Testing effectiveness (Phase 2)UnknownNCT02927340
What this trial is testing

Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Massachusetts General Hospital 30
Not applicableNo Longer AvailableNCT05100134
What this trial is testing

Managed Access Programs for LDK378, Ceritinib

Who this might be right for
Anaplastic Lymphoma Kinase (ALK)- Positive TumorsNon-small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals
Not applicableActive Not RecruitingNCT06269133
What this trial is testing

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants

Who this might be right for
Advanced Non-small Cell Lung Cancer
Regeneron Pharmaceuticals 1,000
Testing effectiveness (Phase 2)Ended earlyNCT04644315
What this trial is testing

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

Who this might be right for
NeoplasmsColorectal NeoplasmsMelanoma+25 more
Hoffmann-La Roche 1
Not applicableLooking for participantsNCT05122806
What this trial is testing

Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

Who this might be right for
Non-small Cell Lung CancerALK Gene Rearrangement Positive
Groupe Francais De Pneumo-Cancerologie 100
Early research (Phase 1)Looking for participantsNCT05142189
What this trial is testing

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
BioNTech SE 320
Large-scale testing (Phase 3)Looking for participantsNCT05722886
What this trial is testing

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Who this might be right for
Haematological MalignancySolid Tumour
Cancer Research UK 825
Next Page